Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture. As the numbers of poorly soluble and complex molecules, such ...

According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...

For the pharmaceutical industry, drug formulation is a cornerstone, crucial for converting bioactive molecules into effective, stable, and patient-friendly medications. For the pharmaceutical industry ...

Entomopathogenic nematodes (EPNs) are widely recognized as effective biological control agents for managing insect pests in agricultural systems. Their ...

Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...

The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for differences in ...